Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
he financing was significantly oversubscribed with high demand from both existing and new investors.
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
The transaction is expected to close in the first quarter of 2022
The company is focused on the development of novel treatments for RNA viruses
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
Advances deployment of mRNA technology across vaccines and therapeutics development
Subscribe To Our Newsletter & Stay Updated
